YOU ARE EXPLORING
Mu Wang, PhD
Associate Professor of Biochemistry & Molecular Biology
Mu Wang, PhD, joined the IU School of Medicine faculty in 2001. He is a tenured Associate Professor specialized in proteomics, DNA repair, cancer drug resistance, and regulation of omega-3 polyunsaturated fatty acids in prostate cancer.
Dr. Wang got his PhD degree in Bio-organic Chemistry from Washington University in St. Louis under the guidance of Dr. John-Stephen Taylor studying DNA photoproduct mutagenesis, which later led him to an interest in DNA repair and a NIH NRSA (F32) postdoctoral fellowship. He became fascinated with the proteomics technologies when they were in their infant stage in late 1990’s and early 2000’s, mainly 2D-gel based technologies. He was the founding director of the Indiana University Proteomics Core Facility in 2001 and an awardee of the Young Investigator Award from the International Human Proteome Organization (HUPO) in 2004.
Dr. Wang currently serves as a principle investigator in the Department of Biochemistry and Molecular Biology, where his main interests are in chemo-drug sensitizer development and the regulation of polyunsaturated fatty acids (PUFAs) in prostate cancer. He also collaborates with a number of basic and clinical investigators for the development of biomarkers for disease diagnosis, prognosis, drug target discovery, and precision medicine. His expertise lies in applying ‘omics’ technologies for large-scale proteomic/metabolomic analysis of cells, tissues, and body-fluids for biomarker discovery and validation.
He served as the Director of the Indiana University Proteomics Core Facility from 2001 to 2016. During this period, he was a Principal Investigator or a Co-Principal Investigator on several prestigious proteomics related federal grants including NCI’s Clinical Proteomic Technologies Assessment for Cancer (CPTAC), NIAID’s Community-Acquired Pneumonia Sepsis Outcome Diagnosis (CAPSOD), the Multiple Myeloma Research Foundation’s Proteomics Centers, and the Indiana 21st Century grant for new instrumentation. He has published more than 90 peer-reviewed articles and book chapters in collaboration with other biomedical investigators.
Chemotherapy is still the primary treatment for many types of cancer. Most cancer patients with the disease are initially responsive to chemotherapeutic treatment. However, drug resistance has become a major impediment to the successful treatment of cancer. To date the mechanism(s) of drug resistance are yet fully understood. Previous studies have suggested that many proteins, such as BRCA1, BRCA2, MDR1, MRP1, MDM2, hMLH1, HSP27, and HSP70, are differentially expressed in drug-resistant tumor cells, such as ovarian tumor cells, by mRNA differential display analysis. Using multiple proteomic platforms, we have identified a panel of potential protein targets that can serve as biomarkers for drug resistance diagnosis and targets for new therapeutic development. My lab is focusing on the use of the cutting-edge proteomic technologies such as MudPIT, label-free protein quantification, and MRM-based protein assays to identify and validate protein biomarker candidates that are the causing factors for certain biological behaviors. Other areas of my research are to develop non antibody-based, high-throughput mass spectrometry-based assays that could quantitatively measure biomarkers from a variety of species in multiplexed fashion and to develop early cancer diagnostic biomarker panels for breast and ovarian cancers.